RWF_VLA-013 (14-241)

Phase Ib Study of Intratumoral CAVATAK (Coxsackievirus A21) and Ipilimumab in Patients with Advanced Melanoma

This study will employ a phase Ib design using the established dose of CAVATAK with ipilimumab in patients with advanced melanoma for whom ipilimumab would be considered standard of care.

Key Eligibility:
* 2.1.1 Patients with metastatic or unresectable stage IIIc or IV melanoma for whom treatment with ipilimumab is indicated and who have at least one cutaneous, subcutaneous tumor or palpable lymph node amenable to intratumoral injection. Histological confirmation of melanoma will be required by previous biopsy or cytology.

* At least one tumor must qualify to be a target lesion for irRC-WHO criteria
Phase Ib
NCT02307149
Cancer, All Other
Cutaneous (skin), Melanoma
Brendan Curti, M.D.
Viralytics Ltd
Chris Fountain
  • Oncology and Hematology Care Eastside